Treosulfan oral versus intravenous in recurrent ovarian cancer. An open-label, randomized, controlled, phase 3-b clinical trial - Treosulfan in ovarian cancer (IOM 10 / 01)

Trial Profile

Treosulfan oral versus intravenous in recurrent ovarian cancer. An open-label, randomized, controlled, phase 3-b clinical trial - Treosulfan in ovarian cancer (IOM 10 / 01)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Sep 2016

At a glance

  • Drugs Treosulfan (Primary) ; Treosulfan (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top